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Abstract
Objectives Affordability and availability of medicinal products depend on governmental policies, 
healthcare budgets and pricing. Pharmaceutical price regulation can improve the accessibility and 
affordability of essential medicinal products. In Europe, medicinal product prices are assigned in-
dividually by each country. The study aimed to compare prices of medicinal products indicated for 
cardiovascular (n = 18) and respiratory disease (n = 9) available for retail in community pharmacies 
in five European countries.
Methods Unit dose medicinal product prices in North Macedonia, Malta, Slovenia, Greece and the 
UK were compared.
Key findings Malta had the highest unit dose prices for the majority (n = 11) of medicinal products 
used for cardiovascular disease and the majority (n = 8) of the medicinal products indicated for 
respiratory disease.
Conclusion Variation in prices of commonly dispensed medicinal products exists. Having a more 
thorough knowledge about the prices of medicines in different countries can contribute to making 
policies that will ultimately make medicines more affordable and accessible to patients.
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Introduction
Medicine affordability is a key parameter in healthcare in terms of 
accessibility to medicines. Affordability and availability of medicinal 
products, in turn, rely on governmental policies, healthcare budgets 
and pricing.[1]
To facilitate national and international comparisons of prices 
of medicinal products, tools such as the External Reference Pricing 
(ERP) and Median Price Ratio (MPR) have been developed. The 
ERP tool that is also known as International Reference Pricing 
(IRP) is widely used to regulate prices of medicinal products and 
helps set the price of a medicinal product in a country by comparing 
prices of medicinal products in different countries. The MPR is a 
measure developed by the World Health Organization (WHO) and 
Health Action International (HAI) used to facilitate national and 
international comparisons of prices of medicinal products. The 
MPR is calculated by dividing the median local unit price with the 
international reference price (IRP).[2] ERP, price control and parallel 
trade help decrease price discrimination between countries and en-
hance access to medicinal products.[3]
The study aimed to compare prices of medicinal products indicated 
for the cardiovascular and respiratory disease available for retail in com-
munity pharmacy in five European countries. The pharmacotherapeutic 
classes were identified as they are directed towards conditions that are 
leading causes of morbidity and mortality worldwide.[4]
Method
Methodology overview
The study setting was Malta and the four countries that were iden-
tified to be included in the study were: North Macedonia, Slovenia, 
Greece and the UK. Data on prices of medicinal products in included 
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use the ERP system or are included in reference pricing exercises by 
other countries, namely the UK.
Selection of medicinal products
Medicinal products indicated for cardiovascular and respiratory 
disease which are dispensed in retail pharmacies and which are avail-
able in the five countries included in the study were compared. The 
final list included 27 medicinal products belonging to 13 different 
pharmacological classes.
Price survey
Data were collected between January 2020 and March 2020. Retail 
unit prices of medicinal products were compared according to the 
active ingredient and rounded up to two significant figures. For each 
country, the cheapest product available for retail having the same 
active ingredient, dosage form and strength was compared. Prices 
of medicinal products in North Macedonia were collected using the 
official virtual medicine registry.[5] Retail prices of the selected medi-
cinal products in Malta were collected from a community pharmacy 
in Valletta. Prices of medicinal products in Slovenia were collected 
from a list of published retail prices of medicinal products from the 
official authorities of the Republic of Slovenia.[6] Retail prices of me-
dicinal products in Greece were accessed through an online platform 
called ‘Galinos’.[7] Prices of medicinal products in the UK were col-
lected from the British National Formulary (BNF), 78th edition.[8]
Data management and statistics
Medicinal product prices were converted to Euro with the monthly 
average exchange rate as of March 2020 as indicated by the 
European Central Bank. The price range, average and standard devi-
ation between countries were calculated for each medicinal product. 
The MPR was determined where possible.
Results
Comparison of prices of medicinal products 
indicated for cardiovascular disease and 
respiratory disease
Malta had the highest price per unit dose for 11 out of the 18 me-
dicinal products indicated for cardiovascular disease. Malta had the 
highest price per unit dose for eight out of the nine medicinal prod-
ucts indicated for respiratory disease (Tables 1 and 2).
In the cases of medicinal products for which the IRP was avail-
able, Malta had the highest MPR for the majority (n  =  5) of the 
medicinal products indicated for cardiovascular disease: amiodarone 
200 mg (4.27), carvedilol 6.25 mg (11.31), enalapril 5 mg (65.64), 
lisinopril 5 mg (11.83) and atorvastatin 10 mg (25.48). Malta had 
the highest IRP for prednisolone 5 mg (7.02), Greece had the highest 
MPR for salbutamol 100  µg (2.84) and Slovenia had the highest 
MPR for salbutamol 2 mg/5 ml (2.84).
Discussion
The study showed variation in prices of commonly dispensed medi-
cinal products in different European countries. Countries included 
in the study had different market sizes, socioeconomic statuses and 
policies. A small market size in a country like Malta, which has a 
particular geographical position, may face challenges such as high 
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being attracted for a wider range of medicinal products of the same 
class or generic equivalents.
North Macedonia which although is not a small as Malta is a 
relatively small country, has a relatively lower cost of living when 
compared to other European countries included in the study and 
a large pharmaceutical manufacturing industry which can be a 
reason why prices of medicinal products are cheaper. Slovenia which 
had lower prices for medicinal products uses measures of cost-
containment to control public pharmaceutical expenditure and re-
duce prices of medicinal products.[9]
Although the UK is used as a reference country, prices of medi-
cinal products in the UK are high. In 2018, the UK National Health 
Services (NHS) highlighted the difficulty with keeping a balance be-
tween providing timely and effective treatment to patients, encour-
aging the pharmaceutical sector to develop novel medicinal products 
and ensuring medicinal product affordability.[10]
Although the majority of countries included in the study use the 
ERP system, the process and availability of the system could vary 
between countries due to lack of transparent price databases that 
may lead to errors in published prices. ERP revisions can occur on an 
irregular basis where price reductions in referencing countries do not 
occur following price reductions in reference countries.
Conclusion
This study can be developed to include more countries to generate 
comprehensive findings in terms of medicinal product pricing in dif-
ferent European countries. Having a thorough knowledge about the 
prices of medicines in different countries can contribute to making 
policies that will ultimately make medicines more affordable and 
accessible to patients.
Author contributions
Emilija Kochova: primary researcher; Janis Vella Szijj: supervisor and reviewer 
and Lilian M. Azzopardi: supervisor and reviewer.
Funding
This research received no specific grant from any funding agency in the public, 
commercial, or not-for-profit sectors
Conflict of Interest
This work has not been previously published and no other submission or pub-
lications will be made. All of the authors listed participated in the study and 
have agreed to the content of the manuscript.
References
 1. Frazier  KC. Affording medicines for today’s patients and sustaining in-
novation for tomorrow. JAMA 2020; 323: 831. https://doi.org/10.1001/
jama.2020.0167
 2. Health Action International. Medicine Prices, Availability, Affordability 
and Price Concepts [online]. 2011. http://www.haiweb.org/medicineprices/ 
(29 September 2020, date last accessed).
 3. Koh  L, Glaetzer  C, Li  Chuen  S et  al. Health technology assessment, 
international reference pricing and budget control told from China’s 
perspective: what are the current developments and future consider-
ations? Value Health Reg 2016; 9: 15–21. https://doi.org/10.1016/j.
vhri.2015.06.004
 4. Ryan JM, Peterson MD, Ryan N et al. Mortality due to cardiovascular 
disease, respiratory disease and cancer in adults with cerebral palsy. 























































































































































































































































































































































































































































































































































































ab004/6154863 by guest on 16 M
arch 2021
4 Journal of Pharmaceutical Health Services Research, 2021, Vol. XX, No. XX
 5. Lekovi Zdravsto Official Virtual Medicine Registry [online]. 2012. 
https://translate.google.com/translate?hl=en&sl=mk&u=https://lekovi.
zdravstvo.gov.mk/drugsregister/overview&prev=search&pto=aue (20 
January 2020, date last accessed).
 6. JAZMP. Agency for Medicinal Products and Medical Devices for The 
Republic of Slovenia [online]. 2020. https://www.jazmp.si/en/human-
medicines/ (21 January 2020, date last accessed).
 7. Galinos Medication Guide [online]. 2020. https://www.galinos.gr/ (21 
January 2020, date last accessed).
 8. British Medical Association and Royal Pharmaceutical Society of Great Britain. 
British National Formulary. 78th ed. London: Pharmaceutical Press, 2019.
 9. Official Gazette of the Republic of Slovenia. Rules on Determining the Prices 
of Medicinal Products for Human Use. [online] 2018. http://www.pisrs.si/Pis.
web/pregledPredpisa?id=PRAV12442 (28 January 2020, date last accessed).
 10. Ewbank L, Omojomolo D, Sullivan K et al. The Rising Cost of Medicines 
to the NHS. What’s The Story? [online] 2018. https://www.kingsfund.
org.uk/sites/default/files/2018-04/Rising-cost-of-medicines.pdf (30 March 








ab004/6154863 by guest on 16 M
arch 2021
